C07D411/14

ELECTROLYTIC SOLUTION, AND ELECTROCHEMICAL DEVICE USING THE SAME
20210408603 · 2021-12-30 ·

An electrolytic solution includes the compound of Formula I and a carboxylate compound:

##STR00001##

The electrochemical device prepared with the electrolytic solution has reduced storage impedance, and improved post-storage swelling, overcharge performance and hot box performance.

Heterocyclic compound and organic light emitting device comprising the same

The present invention relates to a novel heterocyclic compound and an organic light emitting device comprising the same.

Heterocyclic compound and organic light emitting device comprising the same

The present invention relates to a novel heterocyclic compound and an organic light emitting device comprising the same.

Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
11358956 · 2022-06-14 · ·

There are provided compounds having formula (I), in which: X.sup.1 and X.sup.2 are selected from certain combinations of O, S, SO and SO.sub.2; X.sup.3 is selected from CH, CF and N; X.sup.4 is selected from CH and N; X.sup.6, X.sup.6′ and X.sup.6″ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X.sup.7 and X.sup.7′ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X.sup.7 and X.sup.7′ together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I) ##STR00001##

Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119
11358956 · 2022-06-14 · ·

There are provided compounds having formula (I), in which: X.sup.1 and X.sup.2 are selected from certain combinations of O, S, SO and SO.sub.2; X.sup.3 is selected from CH, CF and N; X.sup.4 is selected from CH and N; X.sup.6, X.sup.6′ and X.sup.6″ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X.sup.7 and X.sup.7′ are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X.sup.7 and X.sup.7′ together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I) ##STR00001##

Compositions and methods for treating CNS disorders

Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders. ##STR00001##

4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS

The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds of Formula I,

##STR00001##

or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.

QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.